statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Competition among medical device companies that develop, market and sell equipment to treat and manage patients' obstructive sleep apnea conditions is fierce with ResMed (RMD) currently holding the...

Essential medical device maker files Chapter 11 bankruptcy

(RMD) - Analyzing ResMed's Short Interest

Boris Streubel / Stringer / Getty Images

 Key TakeawaysU.S. equities posted solid gains at midday, lifted by strong tech earnings.Google-parent Alphabet's shares jumped to an all-time high, a day...

Top Stock Movers Now: Alphabet, Newell Brands, Intel, and More

Scott Olson / Getty Images

 Key TakeawaysEli Lilly on Wednesday said its weight-loss treatment, Zepbound, was successful in helping patients with obstructive sleep apnea (OSA).A Phase 3 trial...

Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years

ResMed: Not A Sleeper

Addenda Capital Inc. grew its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 63.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Addenda Capital Inc. Acquires 18,903 Shares of ResMed Inc. (NYSE:RMD)

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on...

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

Needham analyst Michael Matson reiterated a Buy rating on Resmed (RMD Research Report) today and set a price target of $224.00. Michael Matson ha...

Analyst Upgrades Resmed Price Target to $224, Maintains Buy Rating Amidst Market Opportunities and OSA Trial Developments

SeaCrest Wealth Management LLC bought a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and...

SeaCrest Wealth Management LLC Makes New $233,000 Investment in ResMed Inc. (NYSE:RMD)

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Watchers	1,576
52-Wk Low	$132.24
52-Wk High	$229.97

Volume	649,042.00
52-Wk High	$229.97
52-Wk Low	$132.24

Period	Estimated	Reported	Surprise	Result
Q4'24	$2.08	--	--	N/A
Q3'24	$1.93	$2.13	10.51%	BEAT
Q2'24	$1.77	$1.88	5.99%	BEAT
Q1'24	$1.61	$1.64	2.01%	BEAT
Q4'23	$1.67	$1.60	-4.18%	MISSED

RMD Resmed Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals